Peak Bio, Inc.

Equities

PKBO

US70470P1084

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:11:26 2024-05-30 pm EDT			5-day change	1st Jan Change
0.0086 ^USD	-.--%		-.--%	-95.41%

Mar. 05	Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc..	CI
Feb. 16	Peak Bio, Inc. announced that it has received $2.238 million in funding	CI

Peak Bio, Inc. announced that it has received $2.238 million in funding

February 15, 2024

On February 16, 2024, Peak Bio, Inc. closed the transaction. The company issued convertible promissory notes in the aggregate principal amount of $63,000 in its final tranche closing. The company has raised $2,238,000 in the transaction.

Latest news about Peak Bio, Inc.

Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc..	Mar. 04	CI
Peak Bio, Inc. announced that it has received $2.238 million in funding	Feb. 15	CI
Peak Bio, Inc. Receives Loan in the Principal Amount of $750,000	Jan. 29	CI
Peak Bio, Inc. announced that it has received $0.075 million in funding	Jan. 22	CI
Peak Bio, Inc. announced a financing transaction	Dec. 17	CI
Peak Bio, Inc. Appoints Michael Friedman to Board of Directors and Member of Audit Committee and Compensation Committee	23-08-31	CI
Peak Bio, Inc. announced that it expects to receive $100 million in funding from White Lion Capital Llc	23-08-23	CI
Peak Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Peak Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-07-12	CI
Peak Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-29	CI
Peak Bio, Inc. Auditor Raises 'Going Concern' Doubt	23-06-28	CI
Peak Bio, Inc. Announces Resignation of Nevan Elam from Board of Directors	23-06-27	CI
Peak Bio, Inc. announced that it has received $2.195034 million in funding	23-04-27	CI
Peak Bio, Inc. announced that it expects to receive $10 million in funding	23-04-06	CI
Peak Bio, Inc. announced that it has received $0.25 million in funding	23-03-02	CI
Peak Bio, Inc.(OTCPK:PKBO) dropped from S&P TMI Index	23-01-12	CI
Peak Bio, Inc.(OTCPK:PKBO) dropped from NASDAQ Composite Index	23-01-09	CI
Peak Bio, Inc. announced that it expects to receive $0.5 million in funding	22-12-29	CI
Peak Bio, Inc.(OTCPK:PKBO) added to S&P TMI Index	22-12-19	CI
Ladenburg Thalmann Initiates Peak Bio at Buy Rating With $15 Price Target	22-11-04	MT
Peak Bio, Inc. announced that it has received $100 million in funding from White Lion Capital Llc	22-11-03	CI
Peak Bio, Inc.(OTCPK:PKBO) added to NASDAQ Composite Index	22-11-02	CI
Peak Bio, Inc. announced that it has received $25 million in funding from Palo Alto Investors LP	22-10-31	CI
Peak Bio, Inc. Auditor Raises 'Going Concern' Doubt	22-06-16	CI
Peak Bio, Inc. announced that it expects to receive $25 million in funding from Palo Alto Investors LP	22-04-27	CI

Chart Peak Bio, Inc.

Duration

Period

More charts

Company Profile

Peak Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on commercializing therapeutics that aim to improve and address unmet medical needs for patients with inflammatory, rare and specialty diseases and cancer. The Companyâs lead product candidate, PHP-303, is a small molecule, fifth generation, phase II clinical-ready neutrophil elastase (NE) inhibitor (NEI). PHP-303 is an oral, once daily, 0.65 nanomolar, selective, small molecule reversible inhibitor of NE designed to inhibit its bioactive form that the Company is developing for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder that may result in lung disease or liver disease and, potentially, acute respiratory distress syndrome (ARDS). The Companyâs advanced platform in oncology utilizes its toxin, PH-1 or Thailanstatin, to generate a pipeline of antibody-drug-conjugates (ADC) product candidates that are differentiated from traditional ADC-based therapies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PEAK BIO, INC.	-95.41%	199K
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research